Home > Publications

Publications

2207 Publications
Parhofer KG, Pittrow D, Birkenfeld AL, Fraass U, Hohenstein B, Siegert C, Klotsche J, Steinhagen-Thiessen E, Dexl S, Schettler VJJ, Laufs U.

Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.

Clin Res Cardiol. 2026 Feb;115(2):288-303. doi: 10.1007/s00392-025-02719-z. Epub 2025 Aug 4. PMID: 40760109; PMCID: PMC12823742.
Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.
Neue Erkenntnisse aus dem RABBIT-Register zum Krebsrisiko von Patient:innen mit rheumatoider Arthritis bei Therapie mit Januskinaseinhibitoren. [New results from the RABBIT register on the cancer risk of patients with rheumatoid arthritis treated with Janus kinase inhibitors].
Phithak E, Albach FN, Minopoulou I, Biesen R, Kleyer A, Wiebe E, Siegert E, Scholz V, Rehm M, Cheng Q, Sattler A, Bianco S, Fleischmann A, Hermann KG, Walter-Rittel T, Wagner M, Zernicke J, Casteleyn V, Nielsen M, Rose T, Busse A, Hütter-Krönke ML, Keller U, Schneider U, Kawelke L, Ruffer N, Stenzel W, Krönke G, Simon DN, Alexander A.

Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome.

Ann Rheum Dis. 2026 Jan;85(1):212-215. doi: 10.1016/j.ard.2025.09.012. Epub 2025 Oct 23. PMID: 41130878.
Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome.
Burt RK, Alexander T.

Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.

In: Dalakas MC [HRSG]: Immunotherapies for Neurologic Diseases; Handbook of Clinical Neurology Vol. 214. Amsterdam: Elsevier – Health Sciences Division; 2026; pp. 191-216. ISBN: 978-0-323-90887-0; doi: 10.1016/B978-0-323-90887-0.00020-1. PMID: 41526135.
Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.
1 2 3 4 246